BCTX · BriaCell Therapeutics Corp.
$3.59
-0.13 (-3.49%)
At close · Jul 24
Going-concern doubt
— flagged Jun 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Market Cap
$32.36M
Shares
8.70M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$26.31M
-449.1%
FY2025
Diluted EPS
-$62.19
-42.4%
FY2025
Operating Cash Flow
-$28.17M
-16.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $25.81M | $21.27M | $27.18M | $15.34M | $8.02M | $2.02M | |
| $6.21M | $5.93M | $6.15M | $7.94M | $7.27M | $4.96M | |
| — | $15.27K | $15.27K | $15.27K | $15.27K | $15.26K | |
| — | — | — | — | $15.27K | $15.26K | |
| $32.03M | $27.2M | $33.33M | $23.27M | — | — | |
| -$32.03M | -$27.2M | -$33.33M | -$23.27M | -$15.29M | -$6.98M | |
| — | $36.98K | — | — | $979 | $78.55K | |
| $406.78K | $119.96K | $288.02K | $891.21K | $136.73K | $3149 | |
| $475.41K | $114.51K | $262.57K | $850.34K | -$11.55M | -$6.84M | |
| -$218.5K | -$224.21K | -$106.51K | — | — | — | |
| — | $26.56M | $4.93M | $20.3M | -$26.84M | -$13.82M | |
| — | — | — | — | $0 | — | |
| -$30.68M | -$26.31M | -$4.79M | -$20.3M | -$26.84M | -$13.82M | |
| -$301.12K | -$244.27K | -$140.08K | — | — | — | |
| USD/shares | — | -$62.19 | -$43.68 | -$13.00 | -$17.30 | -$30.60 |
| USD/shares | — | -$62.19 | -$43.68 | -$13.00 | -$17.30 | — |
| shares | — | 423.11K | 109.7K | 1.56M | 1.55M | 451.96K |
| shares | — | 423.11K | 109.7K | 1.56M | 1.55M | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.40×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
1.62×
Biotechnology median 7.02×